Swedish Orphan Biovitrum AB (Sobi) today announced that Birgitte Volck, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer (CMO) of Sobi, will leave the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases.
Birgitte will work through a six month notice period before leaving Sobi.
“We thank Birgitte for her leadership and dedication which has helped to evolve Sobi’s patient oriented research and development organisation into a highly skilled international team”, said Geoffrey McDonough, President and CEO of Sobi. “Birgitte joined Sobi in 2012 and has been instrumental in advancing Sobi’s late stage development projects and in bringing new treatment options to people with rare diseases.”
Source: Sobi
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”